10 completed, 1 terminated, 1 withdrawn. 9 Phase 1, 3 Phase 2.
By phase and status
Follow adafosbuvir: new trials by email Literature Review of adafosbuvir trials Research Report on adafosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function AL-335 800 mg, ODV 25 mg, SMV 75 mg - Hepatic Impairment | Phase 1 | Withdrawn | | 2017-09-11 | 2017-10-11 |
A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV) - Healthy | Phase 1 | Completed | 59 | 2017-05-12 | 2017-11-14 |
Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC) Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg - Healthy | Phase 1 | Terminated | 72 | 2017-02-20 | 2017-12-22 |
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive AL-335, Odalasvir (ODV), Simeprevir (SMV) - Hepatitis C, Chronic | Phase 2 | Completed | 33 | 2016-12-21 | 2019-09-11 |
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection AL-335, Odalasvir, Simeprevir - Hepatitis C, Chronic | Phase 2 | Completed | 365 | 2016-11-09 | 2019-11-20 |
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335 AL-335 - Renal Insufficiency | Phase 1 | Completed | 24 | 2016-09-13 | 2017-12-20 |
To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants Drospirenone/ethinylestradiol, AL-335, Odalasvir (ODV) - Healthy | Phase 1 | Completed | 24 | 2016-08-01 | 2017-01-23 |
Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants Odalasvir (ODV), AL-335, Placebo - Healthy | Phase 1 | Completed | 40 | 2016-06-14 | 2018-03-29 |
Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants AL-335, Odalasvir (ODV), Simeprevir (SMV) - Healthy | Phase 1 | Completed | 22 | 2016-05-01 | 2025-02-03 |
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir AL-335, Odalasvir (ODV), Simeprevir (SMV) - Chronic Hepatitis C | Phase 2 | Completed | 161 | 2015-10-31 | 2019-07-16 |
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers AL-335, ACH-3102, Simeprevir - Chronic Hepatitis C | Phase 1 | Completed | 32 | 2015-07-31 | 2019-10-16 |
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 AL-335 matching placebo, AL-335 - Chronic Hepatitis C | Phase 1 | Completed | 112 | 2014-12-31 | 2019-10-16 |
Conditions studied
Hepatitis C, Chronic (5) · Renal Insufficiency (1)
Sponsors
Janssen Research & Development, LLC (8) · Alios Biopharma Inc. (3) · Janssen Pharmaceutical K.K. (1)
Countries
United States (4) · United Kingdom (3) · France (2) · Moldova (2) · Belgium (1) · Canada (1) · Georgia (1) · Germany (1) · Japan (1) · Mauritius (1) · New Zealand (1) · Poland (1) · Singapore (1) · Spain (1)
Results publications
PMID 29736243, PMID 30325939, PMID 30350297
NIH funding
2015 (2), 2016 (1)